BRCA1 and breast carcinoma: Lastly, the use of multi-gene panel testing for hereditary breast cancer risk, not limited to BRCA1/2 pathogenic mutations, is essential to increase the likelihood of detecting an underlying germline genetic component and achieve better PABC patient outcomes.